Mascareñas Pérez-Iñigo, JuanSainz Ordoyo, Cristina2023-06-182023-06-182017Bogdan, Boris y Villiger, Ralph (2007): Valuation in Life Sciences. Springer. Berlin. DiMasi, J. A. (2001): “Risks in new drug development: Approval success rates for investigational drugs”. Clinical Pharmacology & Therapeutics, 69(5) Págs.: 297-307. DiMasi, J.A. et al. (2010): “Trends in risk associated with new drug development: success rates for investigational drugs”. Clinical Pharmacology & Therapeutics, 87 Págs.: 272–277. European Medicines Agency (2017) Accedido el 27 de abril. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000 029.jsp&mid=WC0b01ac0580b18a41 . Fagnan, David E.; Fernández, José M.; Lo, Andrew W. y Stein, Roger M. (2013): “Can Financial Engineering Cure Cancer?”. American Economic Review: Papers & Proceedings, 103(3). Págs.: 406-411 https://ssrn.com/abstract=2203203 . Fagnan, David E.; Gromatzky, Austin A.; Stein, Roger M.; Fernández, José M. y Lo, Andrew W. (2014): “Financing drug discovery for orphan diseases”. Drug Discovery Today. Vol 19, nº 5. Págs.: 533-538 https://doi.org/10.1016/j.drudis.2013.11.009 . Fagnan, David E.; Gromatzky, Austin A.; Stein, Roger M.; Fernández, José M. y Lo, Andrew W. (2014): Supplemental Information and Parameters for “Financing Drug Discovery for Orphan Diseases” https://doi.org/10.1016/j.drudis.2013.11.009 . Fernández, José M.; Stein, Roger M. y Lo, Andrew W. (2012): “Commercializing biomedical research through securitization techniques”. Nature Biotech. Vol 30, nº10. Págs.: 964-975 http://www.nature.com/nbt/journal/v30/n10/full/nbt.2374.html . Fernández, José M.; Stein, Roger M. y Lo, Andrew W. (2012): Supplementary Information for “Commercializing biomedical research through securitization techniques” http://www.nature.com/nbt/journal/v30/n10/full/nbt.2374.html . Fernández, José M.; Stein, Roger M. y Lo, Andrew W. (2015): “Frequently Asked Questions about Megafunds” http://alo.mit.edu/wp-content/uploads/2015/10/FAQ20151005.pdf . Food and Drug Administration (2017) Orphan Drug Product Designation Database. Accedido el 1-mayo-2017. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/ . Food and Drug Administration (2017) Novel Drug Approvals. Accedido el 1-mayo-2017. -2015: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm430302.htm . -2016: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm483775.htm . -2017: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm . Harrington, Scott E. (2009). “Cost of Capital for Pharmaceutical, Biotechnology, and Medical Device Firms” http://dx.doi.org/10.2139/ssrn.1512938 Julián, R y Mascareñas, J (2014): “La Financiación de Proyectos (Project Finance)”. Monografías de Juan Mascareñas sobre Finanzas Corporativas 46. Disponible en: http://ssrn.com/abstract=2407394 . Kaitin, K.I. and DiMasi, J.A. (2010): “Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009”. Clinical Pharmacology and Therapeutics. Vol. 89, nº2. Págs.: 183–188. Kellogg, David; Charnes, John y Demirer, Riza (1999): “Valuation of a Biotechnology Firm: An application of real-options methodology” 3rd Annual Real Options Conference. http://www.realoptions.org/papers1999/Kellogg.pdf . Kim, Esther S., Lo, Andrew W. (2016): “Business models to cure rare disease: a case study of solid biosciences”. Journal of Investment Management. Vol. 14, nº4. Págs.: 87-101 https://ssrn.com/abstract=2864709 . Mascareñas, Juan (2016): “La valoración de un proyecto biotecnológico como una opción real compuesta” En Monografías de Juan Mascareñas sobre Finanzas. http://dx.doi.org/10.2139/ssrn.2316655 . Mathieu, M. (2013): PAREXEL Biopharmaceutical Statistical Sourcebook 2013–2014. Needham, MA: Barnett International. Orfali, M. et al. (2012): “Raising orphans: how clinicaldevelopment programs of drugs for rare and common diseases are different”. Clinical Pharmacology and Therapeutics. Vol. 92, nº 2.Págs.: 262–264. Ou, S. (2011): Corporate Default and Recovery Rates, 1920–2010. Moody’s Investors Service. Paul, S.M. et al. (2010): “How to improve R&D productivity: the pharmaceutical industry’s grand challenge”. Nature Reviews Drug Discovery. Vol. 9, nº3. Págs.: 203–214. https://www.scopus.com/record/display.uri?eid=2-s2.0-77649234756&origin=inward&txGid=58B7ED4961A5FE4B12C124C3ECAFD02E.wsnAw8kcdt7IPYLO0V48gA%3a36 . Seoane-Vasquez, Enrique; Rodriguez-Monguio, R; Szeinbach, Sheryl L. y Visaria, J. (2008): “Incentives for orphan drug research and development in the United States”. Orphanet Journal of Rare Diseases. 3, 33. https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-33 . Thomson Reuters. (2012): “The economic power oforphan drugs”. https://www.thomsonreuters.com/content/dam/openweb/documents/pdf/pharma-lifesciences/white-paper/1001450.pdf .https://hdl.handle.net/20.500.14352/19814En este trabajo se estudia un método propuesto recientemente Fernández, Stein, y Lo (2012), denominado megafondo, con el cuál se incrementa el número de proyectos dentro de una misma entidad y se diversifica la cartera. De este modo, se pueden emitir distintos tipos de títulos para atraer a mayor cantidad de inversores, consiguiendo el capital necesario para conseguir la mencionada diversificación.spamaster thesisopen accessIngeniería financieraCuración de enfermedadesMétodo Megafondo.Finanzas